Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CDK4/6-dependent Solid Tumors”

10 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 10 results

Early research (Phase 1)Looking for participantsNCT07490236
What this trial is testing

Trilaciclib in Combination With Chemotherapy in Patients With CDK4/6-Dependent Solid Tumors

Who this might be right for
TrilaciclibCDK4/6-dependent Solid Tumors
Hebei Medical University Fourth Hospital 100
Early research (Phase 1)WithdrawnNCT05655598
What this trial is testing

TAS-116 Plus Palbociclib in Breast and Rb-null Cancer

Who this might be right for
Advanced Breast CancerTreatment-Refractory Solid TumorsRetinoblastoma Deficiency+4 more
Brown University
Testing effectiveness (Phase 2)Study completedNCT01684215
What this trial is testing

Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer

Who this might be right for
NeoplasmsBreast Neoplasms
Pfizer 61
Testing effectiveness (Phase 2)Study completedNCT05112536
What this trial is testing

Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast CancerBreast Cancer
G1 Therapeutics, Inc. 24
Early research (Phase 1)WithdrawnNCT05905341
What this trial is testing

Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.

Who this might be right for
Breast CancerOvarian CancerLiposarcoma+3 more
Pfizer
Testing effectiveness (Phase 2)Looking for participantsNCT06947811
What this trial is testing

Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations

Who this might be right for
EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor
Sun Yat-sen University 71
Early research (Phase 1)Study completedNCT05538572
What this trial is testing

PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors

Who this might be right for
Breast CancerGlioblastomaHead and Neck Squamous Cell Carcinoma+4 more
Prelude Therapeutics 22
Large-scale testing (Phase 3)Study completedNCT04799249
What this trial is testing

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

Who this might be right for
TNBC - Triple-Negative Breast CancerBreast Cancer
G1 Therapeutics, Inc. 194
Testing effectiveness (Phase 2)Ended earlyNCT04863248
What this trial is testing

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)

Who this might be right for
Metastatic Non-Small Cell Lung CancerNSCLCLung Cancer
G1 Therapeutics, Inc. 10
Testing effectiveness (Phase 2)Ended earlyNCT04887831
What this trial is testing

Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab

Who this might be right for
Urothelial CarcinomaBladder CancerMyelosuppression Adult+2 more
G1 Therapeutics, Inc. 92